Summary & Overview
CPT 0470U: HPV–SEQ NGS Plasma ctDNA Test for Oropharyngeal Cancer
CPT code 0470U is a Proprietary Laboratory Analyses (PLA) code for the HPV–SEQ Test from Sysmex Inostics Inc., an NGS-based circulating tumor DNA assay that quantifies eight DNA targets from HPV types 16 and 18 in plasma to detect minimal residual disease in oropharyngeal cancer. As a PLA code, 0470U applies to a single manufacturer's unique test and is used when clinicians and laboratories report this specific assay. Nationally, such high-sensitivity molecular tests matter for post-treatment surveillance, risk stratification, and precision oncology program planning.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The content outlines payer coverage considerations and typical claims elements for proprietary NGS oncology assays.
Readers will learn what 0470U represents clinically and operationally, the common clinical context for ordering the test, expected site-of-service workflows, and which payers are included in typical coverage discussions. The publication also summarizes typical benchmarking topics and relevant policy and billing considerations for PLA-designated oncology diagnostics. Data not available in the input is identified where applicable.
Billing Code Overview
CPT code 0470U is a Proprietary Laboratory Analyses (PLA) code assigned specifically to the HPV–SEQ Test from Sysmex Inostics Inc. This oncology laboratory test uses next‑generation sequencing (NGS) of cell‑free plasma to detect and quantify minimal residual disease in patients with oropharyngeal cancer by targeting eight specific DNA loci in human papillomavirus (HPV) types 16 and 18.
Service type: Laboratory — Proprietary NGS-based circulating tumor DNA test for HPV
Typical site of service: Clinical laboratory or specialty molecular diagnostics laboratory; specimen collected in an outpatient or ambulatory setting with plasma sent to the performing laboratory for analysis.
Clinical & Coding Specifications
Clinical Context
A 58-year-old patient with previously treated HPV-related oropharyngeal squamous cell carcinoma undergoes post-treatment surveillance. The oncology team orders the 0470U HPV–SEQ Test (Sysmex Inostics Inc.) to detect minimal residual disease by measuring eight specific cell-free HPV16/18 DNA targets in plasma using next-generation sequencing. A peripheral blood draw is collected in a CLIA-certified laboratory collection kit and shipped to the performing lab. The lab performs cell‑free DNA extraction, targeted NGS for the eight HPV DNA targets, quantitation of HPV DNA levels, and reports results to the treating head and neck oncologist and medical oncology team. Clinical workflow steps include test order entry in the electronic medical record, informed consent for genomic testing per institutional policy, specimen collection and couriering, laboratory processing and QA, result interpretation by the ordering clinician, and integration of the result into surveillance decisions and multidisciplinary tumor board discussion.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Unmodified procedure code | When no modifier is required; default billing for the single proprietary PLA test. |
22 | Increased procedural services | If unusually complex laboratory processing or substantial additional work is documented beyond standard procedure. |
52 | Reduced services | When the test is partially performed or scope of testing is reduced and documented (e.g., inadequate sample limits full analysis). |
53 | Discontinued procedure | If specimen collected but testing discontinued for valid documented reasons (e.g., specimen compromised). |
26 | Professional component | When billing separates the professional interpretation component from technical laboratory processing (if applicable under local payer rules). |
TC | Technical component | When only the laboratory technical component is billed and professional interpretation is billed separately (use depends on payer policy). |
Q0 | Investigational clinical service furnished in research program, not otherwise specified | When the test is performed under an approved research protocol and payer requires explicit modifier (follow payer rules). |
Q3 | Laboratory test performed in a demonstration project | When applicable under specific payer demonstration project requirements. |
JW | Drug discarded/not administered (if applicable) | Rarely applicable; included for completeness if a reagent with billing implications is discarded per payer guidance. |
90 | Reference (outside) laboratory | When the specimen is sent to an outside reference lab and billing indicates reference lab service. |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
| 207RH0000X | Hematology & Oncology | Medical oncologists ordering molecular MRD testing. |
| 207RC0000X | Radiation Oncology | Radiation oncologists involved in post-treatment surveillance decisions. |
| 207VN0001X | Pathology – Clinical Pathology | Clinical pathologists overseeing laboratory testing and QA. |
| 2080P0207X | Medical Genetics/Genomics | Molecular geneticists or genomics specialists interpreting NGS-based assays. |
| 363L00000X | Clinical Laboratory | Clinical laboratory directors and lab management responsible for performance and billing of PLA tests. |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
C10.9 | Oropharynx, unspecified malignant neoplasm | Primary site diagnosis commonly associated with HPV-related oropharyngeal cancer surveillance and MRD testing. |
C01.9 | Base of tongue, malignant neoplasm, unspecified | HPV-associated tumor site where HPV–SEQ MRD testing may be ordered for surveillance. |
C02.9 | Malignant neoplasm of other and unspecified parts of tongue | Relevant head and neck cancer subsite for HPV-positive disease monitoring. |
C09.0 | Tonsillar fossa, malignant neoplasm | Tonsil cancers are commonly HPV-driven; MRD testing applicable. |
Z85.118 | Personal history of other malignant neoplasm of head and neck | Used when monitoring for recurrence using sensitive circulating HPV DNA assays. |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
0000U | Proprietary laboratory analyses (example placeholder) | Data not available in the input. |
81479 | Unlisted molecular pathology procedure | Used when an available PLA code does not apply or for additional molecular tests not covered by a specific PLA. |
0010U | Proprietary laboratory analyses (example placeholder) | Data not available in the input. |
86336 | Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative; multiple-step | May be performed in parallel in infectious disease workup but not specific to HPV–SEQ. |
81162 | BRCA1 and BRCA2 full sequence analysis | Represents other tumor-associated genomic testing performed in oncology care pathways. |